Clinical

Articles

"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle. 

Dr. Preston Sprenkle discusses the significance of promoting testicular cancer awareness

Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.

Novel TKI/immunotherapy combo shows promise in advanced kidney cancer

Pieczonka is director of clinical research Associated Medical Professionals in Syracuse, New York.

Fioramonti is a clinical research assistant with Associated Medical Professionals in Syracuse, New York.

"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.

Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma

Podcasts

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Although testicular cancer is rare, it is a disease that providers and patients should still be aware of, says Bradley C. Leibovich, MD, FACS. 

Dr. Leibovich emphasizes the need to increase education on testicular cancer 

Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.

Rare diagnosis of penile cancer causes higher mortality rates and stigma, expert says

Videos

“The important thing to know is that…we…aim to focus on the regions…that were not under the light of research education, in particular in the [genitourinary] space,” says Andrea Necchi, MD.

Why clinicians should join the Global Society of Rare Genitourinary Tumors

“Andrea and I lead this from [a] President/Vice President standpoint, but we also have a group of leaders from around the world, really representing all ethnicities, genders and others, because we wanted to make sure [that] we're inclusive, andmeet the needs and expectations of everybody,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

Dr. Spiess and Dr. Necchi on new society for rare GU cancers

In a recent interview, Philippe E. Spiess, MD, and Andrea Necchi, MD, shared how they aim to develop an environment that emphasizes education, patient advocacy, and clinical research for rare genitourinary cancers.

New society for rare genitourinary cancers aims to build education and awareness

“The geographical discrepancies, the social discrepancies, and the impact of these discrepancies in the possibility for the patient to access any type of cure or surgical intervention is critical,” says Andrea Necchi, MD.

Genitourinary Cancers